Lisocabtagene maraleucel may induce remission in relapsed ch

1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% of fatalities were thought to be due to liso-cel related complications. Evidence Rating Level: 1 (Excellent) Study Rundown: There exist limited options for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic

Related Keywords

United States , , Rating Level , First Line Venetoclax Combinations , Chronic Lymphocytic , Between Jan , Chronic Lymphocytic Leukemia , Chronic Lymphocytic Leukemia Cll , Hematologic Cancer , Hematologic Malignancy , Hematology , Hematology Oncology , Lisocabtagene Maraleucel , Oncology , Small Lymphocytic Lymphoma , Chronic Disease ,